SCHEMBL168919

SCHEMBL168919

O=C(c1ccccc1)C1CCCN1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.54
MCL1 Q07820 1/20 0.46
SCN4A P35499 1/20 0.45
RIPK1 Q13546 1/20 0.45
CTSC P53634 1/20 0.45
DPP4 P27487 2/20 0.43
HTR2C P28335 1/20 0.43
HTR2B P41595 1/20 0.43
DPP8 Q6V1X1 1/20 0.43
ANPEP P15144 1/20 0.42
KMT2A Q03164 1/20 0.42
CYP1A2 P05177 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C19 P33261 2/20 0.41
CYP3A4 P08684 1/20 0.41
KDM4E B2RXH2 1/20 0.41
NPC1 O15118 1/20 0.41
HPGD P15428 1/20 0.41
MAPK1 P28482 1/20 0.41
RAB9A P51151 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20482434 1.00 ELANE (0.54) ELANEMCL1SCN4ARIPK1CTSC
SCHEMBL20482162 1.00 ELANE (0.54) ELANEMCL1SCN4ARIPK1CTSC
SCHEMBL5357416 0.95 ELANE (0.49) ELANEMCL1SCN4ARIPK1CTSC
SCHEMBL14994604 0.95 ELANE (0.49) ELANEMCL1SCN4ARIPK1CTSC
Hydrochloric Acid SCHEMBL1251429 0.93 ELANE (0.48) ELANEMCL1CTSCCYP2D6CYP3A4
Trifluoroacetic Acid SCHEMBL5423645 0.91 ELANE (0.47) ELANEMCL1SCN4ARIPK1CTSC
Trifluoroacetic Acid SCHEMBL5423648 0.91 ELANE (0.47) ELANEMCL1SCN4ARIPK1CTSC
SCHEMBL28854337 0.90 ELANE (0.49) ELANERIPK1CTSCKMT2ANPC1
SCHEMBL28854336 0.90 ELANE (0.49) ELANERIPK1CTSCKMT2ANPC1
SCHEMBL27623273 0.84 ELANE (0.43) ELANESCN4ARIPK1HTR2CHTR2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110325512-A The method for being used to prepare chiral pyrrolidine -2- base carbinol derivatives 豪夫迈·罗氏有限公司 2019-10-11 CN disclosed
EP-2611441-A1 BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES F.HOFFMANN-LA ROCHE AG (CH) 2013-07-10 EP disclosed
CN-103079562-A BACE inhibitors for use in the treatment of diabetes HOFFMANN LA ROCHE 2013-05-01 CN disclosed
WO-2012028563-A1 BACE INHIBITORS FOR USE IN THE TREATMENT OF DIABETES F. HOFFMANN-LA ROCHE AG (CH) 2012-03-08 WO disclosed
US-20120053200-A1 BACE 2 INHIBITORS HOFFMANN-LA ROCHE INC. 2012-03-01 US disclosed
CN-102260265-A Hexahydro-pyrrole[3,4-b] pyrrole derivative, its preparation method and application 2011-11-30 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053200-A1 BACE 2 INHIBITORS BACE2, BACE1, PSEN2 ELANE 3069/4885MCL1 3253/4885SCN4A 1565/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.